Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 588 of 6351
-
New mRNA vaccine aims to stop cancer from coming back
Disease control Recruiting nowThis study is a phase I clinical trial of multi-center, open label, dose increase and dose expansion. It aims to evaluate the safety, tolerance, PK characteristics, immunogenicity and initial efficacy of personalized new antigen mRNA vaccine RGL-270 (hereinafter referred to as RG…
Phase 1 • Sponsor: Xian-Jun Yu • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Could dimephosphon help stroke patients recover faster?
Disease control Recruiting nowA multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dimephosphon® in acute ischemic stroke
Phase 3 • Sponsor: Tatchempharmpreparaty, JSC • Aim: Disease control
Last updated Jun 26, 2026 15:28 UTC
-
New combo therapy aims to boost rectal cancer remission
Disease control Recruiting nowThis study aims to evaluate the efficacy and safety of short-course radiotherapy combined with CAPOX plus bevacizumab with or without a PD-1 inhibitor in patients with locally advanced rectal cancer (LARC). The hypothesis is that the addition of immunotherapy (PD-1 inhibitor) can…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New device could replace opioids for weeks of pain relief after surgery
Symptom relief CompletedPostoperative pain remains undertreated with inadequate analgesic options. Opioids have well-known limitations for both individuals and society; single-injection and continuous peripheral nerve blocks provide intense analgesia but are limited in duration to 24-72 hours; and curre…
Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Farming for life: kenyan study aims to fight hunger in pregnant moms
Disease control Recruiting nowScarcity of food is a leading cause of sickness and death in mothers and their newborns in sub-Saharan Africa. Use of locally acceptable agricultural interventions including provision of agricultural supplies, training and having model farms can go a long way to alleviate the ill…
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New HIV combo could free patients from daily pills
Disease control Recruiting nowThere is no cure for HIV infection. Antiretroviral therapy (ART) is widely available but requires daily, life-long intake. This can cause issues around side-effects, resistance, adherence and stigma. A new therapy, broadly neutralising antibodies, (bNAbs), may work as well as ART…
Phase 2 • Sponsor: University of Oxford • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Experimental CAR-T therapy targets stubborn autoimmune disease
Disease control Recruiting nowThe goal of this clinical trial is to test the safety and potential benefit of a new immune cell therapy called anti-BCMA-CD19 CAR-T cells in adults (18-75 years) with IgG4-related disease (IgG4-RD) that has come back or not improved after standard treatments such as glucocortico…
Phase 2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 26, 2026 12:38 UTC
-
New drug could shrink eye tumors, saving sight
Disease control Recruiting nowThis is a prospective, single arm, phase II clinical trial of neoadjuvant Tebentafusp (KIMMTRAK®) in patients with locally advanced primary uveal melanoma. Patients must be HLA-A\*02:01 with large, surgically unresectable (other than complete enucleation of the eye) primary uveal…
Phase 2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New dynamic duo targets Hard-to-Treat liver cancer
Disease control Recruiting nowPhase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)
Phase 1/2 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a double-barrel cholesterol drug shrink artery plaque better than statins alone?
Disease control Recruiting nowA multicenter cohort study
Sponsor: Changhai Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Bhangra beat: could folk dance be the key to better metabolic health?
Prevention CompletedYou are invited to take part in a research project. Before you decide if you would like to take part, please read this information sheet carefully. You can also ask the lead researcher if you have any questions (please see contact details at the end of this sheet). Title of Proj…
Sponsor: University of Wolverhampton • Aim: Prevention
Last updated Aug 19, 2026 00:00 UTC
-
Could a custom vaccine stop cancer before it starts in lynch syndrome?
Prevention Recruiting nowTha aim of this clinical trial is to evaluate safety and tolerability of autologous peripheral blood differentiated and matured adult dendritic cells. Immunogenicity of the prduct(DC-DELAY) will be evaluated also.
Phase 1 • Sponsor: Fundacion Clinic per a la Recerca Biomédica • Aim: Prevention
Last updated Jun 27, 2026 12:06 UTC
-
New strategy targets lingering lymphoma DNA in seniors
Disease control Recruiting nowOlder patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity. Identifying which patients might benefit from more therapy at the end of first-line treatment is important. The ability to me…
Phase 2 • Sponsor: Danielle Wallace • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cocktail aims to turn inoperable stomach cancer into operable tumors
Disease control Recruiting nowThis study aims to evaluate the efficacy of disitamab vedotin in combination with sintilimab and SOX as conversion therapy in patients with initially unresectable locally advanced or metastatic gastric cancer exhibiting HER2 IHC 1+/2+ expression. The trial plans to enroll patient…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New antibody therapy shows promise for rare amyloidosis
Disease control Recruiting nowThis is a prospective, single-arm, single-center clinical study designed to evaluate the efficacy and safety of low-dose BCMA/CD3 bispecific antibody (CM336) in patients newly diagnosed with systemic light chain (AL) amyloidosis.
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThe purpose of this study is to determine the safety, tolerability and preliminary efficacy of NEUK203-215 , a healthy donor (HD) allogeneic CD19/BCMA-targeted CAR-NK cell product, in participants with severe, refractory autoimmune diseases. This study plans to conduct an interi…
Early phase 1 • Sponsor: Neukio Biotherapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New shot aims to free hepatitis b patients from daily pills
Disease control Recruiting nowThis is an open-label, multicenter, Phase 2 study designed to evaluate the efficacy and safety of AHB-137 injection in participants with chronic hepatitis B (CHB) with low hepatitis B surface antigen (HBsAg) levels.
Phase 2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Donor immune cells aim to tame autoimmune attacks
Disease control Recruiting nowThe purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.
Phase 1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for Tough-to-Treat blood cancers: phase 3 trial launches
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent …
Phase 3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
AstraZeneca launches human tests for bird flu vaccines
Vaccine OngoingThe purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
Phase 1/2 • Sponsor: AstraZeneca • Aim: Vaccine
Last updated Jul 22, 2026 00:00 UTC